This site is intended for healthcare professionals

Ascendis Pharma A/S receives European approval for TransCon hGH for pediatric growth hormone deficiency.

Read time: 1 mins
Published:18th Jan 2022
Ascendis Pharma A/S announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin. Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone (also known as growth hormone deficiency, or GHD).

TransCon hGH is a prodrug of somatropin that provides sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body.

The EC approval is based on clinical results submitted in the Marketing Authorisation Application (MAA), including data from the Company’s Phase III heiGHt, fliGHt and enliGHten Trials, which collectively treated more than 300 pediatric patients diagnosed with GHD, as well as data from a non-clinical safety program.

In August 2021, the FDA approved TransCon hGH (as Skytrofa ) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone. TransCon hGH is also in development for pediatric GHD in Japan and China.

Condition: Growth Hormone Deficiency
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.